key: cord-0814216-8ljth1zk
authors: Lei, Ji; Coronel, María M.; Yolcu, Esma S.; Deng, Hongping; Grimany-Nuno, Orlando; Hunckler, Michael D.; Ulker, Vahap; Yang, Zhihong; Lee, Kang M.; Zhang, Alexander; Luo, Hao; Peters, Cole W.; Zou, Zhongliang; Chen, Tao; Wang, Zhenjuan; McCoy, Colleen S.; Rosales, Ivy A.; Markmann, James F.; Shirwan, Haval; García, Andrés J.
title: FasL microgels induce immune acceptance of islet allografts in nonhuman primates
date: 2022-05-13
journal: Science advances
DOI: 10.1126/sciadv.abm9881
sha: 818546fae9750eac365d5cabf89ef436e8301bcc
doc_id: 814216
cord_uid: 8ljth1zk

Islet transplantation to treat insulin-dependent diabetes is greatly limited by the need for maintenance immunosuppression. We report a strategy through which cotransplantation of allogeneic islets and streptavidin (SA)–FasL–presenting microgels to the omentum under transient rapamycin monotherapy resulted in robust glycemic control, sustained C-peptide levels, and graft survival in diabetic nonhuman primates for >6 months. Surgical extraction of the graft resulted in prompt hyperglycemia. In contrast, animals receiving microgels without SA-FasL under the same rapamycin regimen rejected islet grafts acutely. Graft survival was associated with increased number of FoxP3(+) cells in the graft site with no significant changes in T cell systemic frequencies or responses to donor and third-party antigens, indicating localized tolerance. Recipients of SA-FasL microgels exhibited normal liver and kidney metabolic function, demonstrating safety. This localized immunomodulatory strategy succeeded with unmodified islets and does not require long-term immunosuppression, showing translational potential in β cell replacement for treating type 1 diabetes.

Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic islet  cells (1) . Its prevalence in the United States has risen steadily since the 1980s, with T1D afflicting >1.5 million Americans (2) . Transplantation of pancreatic islets from cadaveric donors offers restoration of  cell mass in T1D patients with the potential for prevention and reversal of diabetic complications (3) . Nonetheless, islet graft recipients must be immunosuppressed for the rest of their lives with agents that not only are toxic to the recip ient and graft  cells but also may induce peripheral insulin resist ance (4) . Thus, the development of tolerogenic regimens that obviate the need for immunosuppression will facilitate the broad application of islet transplantation as a cure for T1D.

Immune tolerance was first demonstrated in smallanimal mod els more than 6 decades ago (5) . Intensive efforts assessing various toleranceinducing strategies (6) (7) (8) , such as lymphocyte depletion, costimulatory blockade, and administration of T regulatory cells (T regs ), tolerogenic dendritic cells, apoptotic donor leukocytes, and myeloidderived suppressor cells, have not translated into a protocol with efficacy in the clinic. Mixed hematopoietic chime rism has so far been the only protocol to achieve clinical toler ance, but only in a small number of patients (9) . Whereas donor chimerism-induced transplant tolerance in kidney recipients rep resents a groundbreaking advance for the field, this approach suffers from the requirement for intensive conditioning to achieve donor chimerism and the potential for acute or chronic graftversus host disease (10) . Similarly, in nonhuman primates (NHPs), the gold standard translational model for allogeneic transplantation, only mixed chimerism has induced tolerance to samedonor kidney al lografts (11) . A recent nonchimeric approach using peritransplant administration of apoptotic donor lymphocytes under the cover of an induction regimen consisting of rapamycin, antiCD40 and interleukin6R (IL6R) antibodies, and soluble tumor necrosis factor receptor (TNFR) reported ~1year islet allograft survival in NHPs (8) . However, the clinical application of this protocol may be limited as graft survival was achieved only in single major histocompatibility complex (MHC) class II DRB allele matched recipients and required one dose of cell infusion 1 week before transplantation.

The Fas receptor/Fas ligand (FasL) pathway plays crucial roles in activationinduced cell death and tolerance to selfantigens (12) . The efficacy of FasL gene therapy to mitigate allogeneic immune responses for graft acceptance has been demonstrated in experi mental animal models (13, 14) . Nevertheless, the uncertain safety profile of sustained ectopic expression of FasL in target tissues, op posing properties of soluble versus membranebound forms of FasL (15, 16) , and technical and regulatory challenges of gene therapy severely curtail clinical applicability. To investigate the translational potential of FasL as an immunomodulatory agent, our group con structed a chimeric protein consisting of the extracellular domain of FasL with the core streptavidin protein (SA), SAFasL. SAFasL ex ists as multimers with robust apoptotic activity on Fasexpressing cells and lacks the matrix metalloproteinase-cleavable sites pre sent in its native extracellular domain (17) . Pancreatic islets chemi cally modified to present SAFasL protein on their surface survive indefinitely under the kidney capsule in the absence of chronic immunosuppression in an allogeneic transplant murine model (18) . However, the requirement for chemical modification of the islet surface to present SAFasL limits translation of this approach into the clinic. For this reason, we recently engineered poly(ethylene gly col) (PEG)-based synthetic hydrogel microspheres (microgels) for controlled presentation of bioactive SAFasL (19) . Cotransplanta tion of SAFasL-presenting microgels with unmodified allogeneic islets under transient cover of rapamycin resulted in longterm en graftment and function in diabetic mice. Recipients generated normal systemic responses to donor antigens, implying immune privilege of the graft, and FoxP3 + T regs were instrumental in graft acceptance as their deletion resulted in prompt graft rejection. Thus, this biomaterial based strategy offers offtheshelf immunomodulatory capability without modification of donor islets, increasing its clinical relevance and breadth of potential clinical applicability. Here, we investigated the immunomodulatory potential of the SAFasL microgel technology in a preclinical streptozotocin (STZ)-induced diabetes NHP model in which allogeneic islets and SAFasL microgels are cotransplanted to the omental pouch.

In the clinic, intraportal administration to lodge islets inside the liv er has been used almost exclusively and is the only site with demon strated efficacy for sustained graft function (20) . Infusion of islets into the portal system, however, triggers activation of platelets, co agulation factors, and the complement system, resulting in signifi cant acute loss of islets (21) . The omentum is an alternative site ideal for the colocation of islets and immunomodulatory microgels, providing a capacious site to host the material, rich access to capil lary beds, and delivery of insulin into the portal circulation (22, 23) . Here, we evaluated SAFasL-presenting microgels for sustained survival and function of transplanted allogeneic islets transplanted to the omentum with a thrombininduced fibrin matrix per the Miami protocol (23) (Fig. 1A) .

We previously demonstrated that cotransplantation of SA FasL-presenting microgels with allogeneic islets under a transient cover of rapamycin resulted in indefinite graft survival in mice (19) . This protocol was adopted for the present NHP study except for the rapamycin regimen (as detailed below) because of differences in metabolic and pharmacological dynamics between NHPs and ro dents (24) . For the present study, the rapamycin transient regimen was informed by a combination of toxicity knowledge derived from previous clinical reports (25) and our decadelong experience as to what would be tolerable and functional levels in NHPs to achieve possible graft protection. Biotinylated PEG microgels (150 m diameter) were synthesized by microfluidic polymerization and functionalized with SAFasL as described (19) . This synthetic bio material provides a highly reproducible platform for controlled pre sentation of SAFasL ( fig. S1 ). Four diabetic NHPs ( Fig. 1B tables S1 and S2) underwent transplantation of allogeneic islets [14,800 to 18,700 islet equivalents (IEQ)/kg] mixed with SAFasLpresenting microgels (150,000 to 200,000 microgels delivering 0.2 mg of SAFasL) at the omental surface. A 3month course of rapamycin monotherapy was used-target rapamycin blood trough level of 40 ng/ml for the first 2 weeks and then 20 ng/ml until the 3month time point after transplantation, when rapamycin was dis continued without weaning. Rapamycin levels became undetectable 2 weeks after discontinuation. We note that our prior studies (7, 26) and other studies (27) showed that rapamycin monotherapy could not prevent islet graft rejection even at levels >50 ng/ml in allogene ic NHP models. Three diabetic NHPs ( Fig. 1B and tables S1 and S2) had allogeneic islets (19,300 to 20,000 IEQ/kg) cotransplanted with unmodified PEG microgels lacking SAFasL protein into the omen tum under a similar course of rapamycin which served as a control. After islet transplantation, prompt glycemic control was achieved and maintained by all animals receiving SAFasL-presenting mi crogels for observation periods >134, >170, >177, and >188 days (Fig. 2 , A and B, and figs. S2 and S3). Animals were terminated with functioning grafts due to coronavirus disease 2019 (COVID19) pandemic-associated institutionimposed logistical barriers. In contrast, control subjects, which received an identical rapamycin regimen and had comparable rapamycin plasma levels (P = 0.63; fig. S4 , D and E) but no SAFasL, maintained glycemic control for only 21, 27, and 35 days with a mean survival time of 27.7 days (Fig. 2 , A and E, P = 0.010, and figs. S3 and S5). Figure 2B presents nonfasting blood glucose levels (left axis) and administered external total daily insulin requirement (EIR; right axis) averaged across all SAFasL-presenting microgel recipients; fig. S2 (A to D) depicts data for individual recipients. Before islet transplantation, animals in the SAFasL Microgel group had aver age nonfasting blood glucose levels around 400 mg/dl and required 16 to 22 units of exogenous insulin per day. After transplantation, the fasting blood glucose levels were in the normal range for all animals [using intravenous glucose tolerance tests (IVGTT) time 0 reading at 1, 3 and 6 months as subjects were fasted overnight ( Fig. 2C) ], but postprandial glucose levels for some animals fluctu ated between normal and occasionally >300 mg/dl. Nevertheless, SAFasL Microgel subjects maintained excellent glycemic control within the normal range for the duration of the study (postSTZ/ pretransplant versus posttransplant, P = 0.0035) (Fig. 2B ). Three SA FasL Microgel subjects required exogenous insulin after transplan tation, but only 10 to 20% of the pretransplant dose to maintain postprandial blood glucose levels below 250 mg/dl ( fig. S2 , A to C). Subject 4 (M9118) initially required one to two units of insulin per day but developed a fully functioning graft requiring occa sional exogenous insulin at 4 months after transplantation ( fig.  S2D ). For SAFasL Microgel subjects, posttransplant EIR was sig nificantly lower than postSTZ/pretransplant (P = 0.0092). All animals experienced initial weight loss after STZ induction and after transplantation, but they gradually recovered, indicating that post transplant euglycemia was not due to malnutrition ( fig. S2 , E to H). It is expected that both STZ induction and the transplant surgery will cause immediate weight loss. The continued initial minor weight loss after transplantation is most likely associated with rapamycin therapy. Results for metabolic markers indicated normal liver and kidney function for SAFasL Microgel NHPs ( fig. S4 , A to C, blue lines). After surgical removal of islet grafts at the end of the study, SAFasL Microgel animals promptly returned to a diabetic state (blood glucose levels: posttransplant versus postgraft explant, P < 0.0001; EIR: posttransplant versus postgraft explant, P = 0.0042) ( Fig. 2B and fig. S2 , A to D), demonstrating that blood glucose con trol was due to the graft.

At selected time points, IVGTTs were performed to assess glu cose disposal kinetics and insulin and Cpeptide levels. After glu cose bolus challenge, SAFasL Microgel subjects returned to normal blood glucose levels within 90 min, with comparable profiles to that of naïve animals before diabetes induction [area under the curve (AUC) analysis: preSTZ (naïve) versus postSTZ (after STZ induc tion but before transplant), P < 0.0001; 3 months after transplant versus postSTZ, P < 0.0001; 6 months after transplant versus post STZ, P = 0.0002] (Fig. 2C ). After removal of the graft, blood glucose levels remained elevated and equivalent to pretransplant diabetic levels (AUC: postgraft removal versus postSTZ, P = 0.0760), demonstrating that the control of blood glucose levels was due to the graft. Consistent with these metrics of graft function, back ground levels of insulin and Cpeptide were measured in the serum of SAFasL Microgel NHPs after STZ administration but before is let transplant and equivalently low levels were evident after graft removal with most (three of four) animals with A1C levels below 6% at the end of the study. We detected the presence of SAFasL protein in the serum of all subjects as early as 1 day after transplantation rang ing from 4 to 56 ng/ml and decreasing to background levels by days 7 to 14 (fig. S2, I to L). This result is consistent with prior in vivo mea surements of SAFasL microgels in mice, showing a local halflife of 3.0 days (19) . Figure 2E presents random nonfasting blood glucose levels (left axis) and total daily EIR (right axis) averaged across all recipients receiving control microgels (referred to here as simply "Microgel"); data for individual recipients are provided in fig. S5 (A to C). Before islet transplantation, Microgel subjects had average nonfasting blood glucose levels around 400 mg/dl while requiring 15 to 20 units of exogenous insulin per day. After transplantation, Microgel sub jects experienced uneventful recovery, and average blood glucose levels returned to the normal range. However, around day 30 after transplantation, blood glucose levels and required external insulin dose increased and remained elevated at levels comparable to the diabetic pretransplantation state, indicating graft rejection (blood glucose levels: and Cpeptide levels at 1 month after transplantation remained at pretransplant diabetic levels (insulin: preSTZ versus postSTZ, P < 0.0001; 1 month after transplant versus postSTZ, P = 0.9504; Cpeptide: preSTZ versus postSTZ, P < 0.0134; 1 month after transplant versus postSTZ, P > 0.9999) (Fig. 2G ). Autopsy pathology showed normal hematoxylin and eosin (H&E) staining for liver, heart, lung, kidney, and intestinal tissue for SAFasL Microgel NHPs ( fig. S6A ). Recipient pancreases contained few small isletlike clusters of endocrine cells but were devoid of insulinpositive  cells ( fig. S6B ), indicating effective elimination of host  cells by STZ treatment and confirming that posttransplant glycemic control is attributable to the graft. Histo logical analyses of the omentum transplant site for SAFasL Microgel NHPs revealed numerous wellgranulated clusters of cells reminis cent of islets with minimal to no infiltrating lymphocytes, suggest ing the absence of rejection (Fig. 3A) . Histology of omentum for Microgel subjects revealed isletlike clusters that were infiltrated by lymphocytes, consistent with graft rejection (Fig. 3A) . Immunos taining of the graft site demonstrated wellpreserved insulin + struc tures corresponding to transplanted islets in longterm (day 177) SAFasL Microgel NHPs, whereas sections for Microgel control NHPs at rejection (day 21) show structures with loss of insulin staining at the periphery ( fig. S7 ). Immunostaining analyses of the graft site demonstrated the presence of FoxP3 + (a marker of T regs ) cells at a higher frequency (cell count, intensity) in SAFasL Micro gel NHPs compared to Microgel subjects (FoxP3 + cell counts: P = 0.0143; FoxP3 + intensity: P = 0.043; Fig. 3 , B to D). This finding is in agreement with studies in diabetic mice demonstrating a pivot al role for T regs in establishing SAFasL microgel-induced immune acceptance (19) . Similarly, no differences in CD28 + CD95 − CD4 + or CD8 + naïve, CD28 + CD95 + CD4 + or CD8 + central memory, and CD28 − CD95 + CD4 + or CD8 + effector memory T cells were observed over time (CD4 + naïve: P = 0.4621 and P = 0.5102; CD8 + naïve: P = 0.2524 and P = 0.5626; CD4 + central memory: P = 0.5977 and P = 0.4785; CD8 + central memory: P = 0.4420 and P = 0.4790; CD4 + effector memory: P = 0.4815 and P = 0.4829; CD8 + effector memory: P = 0.2442 and P = 0.0844). The lack of differences in these im mune cell populations in systemic circulation over time for SA FasL Microgel animals is expected as we previously showed that the immunomodulatory effects of SAFasL are localized to the graft (18, 19) .

Generation of IgG antibodies against donor MHC antigens was assessed by flow cytometry before and at multiple time points after transplantation. No positive donorspecific antibodies to MHC class I (P = 0.2904) or MHC class II (P = 0.0758) were detected over time in SAFasL Microgel subjects (Fig. 5, A and B ). In contrast, there was a significant increase in the titers of antibodies to MHC class II (P = 0.0326), but not class I (P = 0.3292), in the serum of control Microgel NHPs at 1 month after transplantation (Fig. 5,  A and B) . Mixed lymphocyte reactions against donor and third party CD4 + and CD8 + T cells also revealed unchanged responses between pre and posttransplant conditions for SAFasL Microgel NHPs (CD4 + donor: P = 0.4200; CD4 + thirdparty: P = 0.6949; CD8 + donor: P = 0.4145; CD8 + thirdparty: P = 0.7858) (Fig. 5 , C to F). Although Microgel subjects exhibited unchanged CD4 + T cell response against donor (P = 0.6082) and thirdparty (P = 0.0555) stimulators, the CD8 + T cell compartment showed in creased responses toward both donor (P = 0.0057) and thirdparty (P = 0.0216) antigens ( S10E ). These results show that antibodies against SAFasL develop ~2 weeks after transplantation, when SAFasL is undetectable systemically, and primarily are against the SA moiety of the chime ric protein. The presence of such antibodies did not negatively af fect the efficacy of our protocol in sustaining allogeneic islet graft survival.

Achieving indefinite survival of allogeneic grafts without chronic immunosuppression remains an elusive goal in clinical trans plantation. For islet transplantation in particular, a reliable and safe tolerogenic regimen could expand the therapeutic application of islet transplantation for T1D given the delicate risk/benefit considerations balancing restoration of  cell function with immu nosuppression toxicities (28) (29) (30) (31) (32) . Here, we demonstrate that SAFasLpresenting microgels cotransplanted with allogeneic islets are effective in sustaining longterm (>6 months) survival and excellent glycemic control in diabetic NHPs without chronic immunosup pression. These subjects demonstrated glucoseresponsive insulin secretion and Cpeptide levels comparable to the prediabetic state. In marked contrast, control animals cotransplanted with microgels without SAFasL rejected the islet graft acutely. Sustained survival was associated with an increased number of FoxP3 + (a marker of T regs ) cells at the graft site without a detectable change in systemic frequency of various immune cell populations. The pre and post transplant proliferative responses of CD4 + and CD8 + T cells to do nor and third party stimulators were equivalent for subjects that received SA FasL-presenting microgels, indicating the lack of sys temic unresponsiveness. In addition, NHPs receiving SAFasLpresenting microgels did not reveal changes between pre and posttransplant IFN-secreting cell numbers and antidonor MHC antibodies. In contrast, subjects that received control microgels generated antibodies against donor MHC molecules and exhibited increased CD8 + T cell proliferative responses to donor and thirdparty antigens. Increased numbers of FoxP3 + cells in the graft site and unchanged systemic T cell frequency and responses to do nor antigens are consistent with our studies in rodents, demonstrat ing that SAFasL confers localized tolerance to the graft that requires T regs (18, 19, 33) . Our results are consistent with prior work demon strating the role of T regs in "induced" immune privilege to allografts (34, 35) . T regs were shown to protect allogeneic hematopoietic stem cells in naïve recipients by colocalizing in the marrow cavity (34) , and immune privilege mediated by T regs was also shown for skin and lung allografts (36, 37) . T regs manifest their suppressive function by various means, including converting T effector cells into T regs (38) , altering the function of dendritic cells within draining lymph nodes (39) , and expression of various immunoregulatory cytokines and chemokines (40, 41) . Last, subjects receiving allogeneic islets and SAFasL microgels exhibited normal liver and kidney metabolic function and organ histology and continued to gain weight, indicat ing that the immunomodulatory biomaterial has an acceptable safety profile. We did not observe any of the reported FasL toxicity (42) (43) (44) , which we attribute to the form and local presentation of SAFasL. Although diabetic NHPs receiving allogeneic islets cotransplanted with SAFasL microgels displayed longterm islet acceptance and normal fasting glycemic control, they did not achieve insulin indepen dence. Nevertheless, there was 80 to 90% reduction in EIR as com pared with the pretransplant diabetic levels to control postprandial blood glucose. The idea that insulin independence was not achieved is not unexpected as NHP allogeneic islet transplantation is com plex and demanding, and singledonor islet transplantation (as done in this study) generally represents a marginal islet mass. Similarly, islet mass from a single donor is generally insufficient to restore full euglycemia in human islet transplantation. The Clinical Islet Trans plant Consortium registration trials for islet alone and islet after kidney transplantation found that only ~20% of patients were rendered normoglycemic after single human donor islet transplantation (45) . The same issue applies to alloislet NHP transplantation. The sustained Cpeptide levels, improved glycemic control, and results of the periodic IVGTT document stable and robust islet function. Notably, we did ob serve gradual improvement in islet graft function in three of four recip ients of allogeneic islets cotransplanted with SAFasL microgels, and one recipient almost achieved stable insulin independence toward the end of the study, indicating the efficacy and stability of the protocol in controlling chronic immune responses to the graft.

MHC typing demonstrated that all donorrecipient pairs were overall incompatible. However, for both SAFasL Microgel and con trol cohorts, each group has only one pair of animals that were MHC fully mismatched, whereas all other pairs were either MafaA or MafaB haploidentical or MHC haploidentical due to limited animal selection to achieve MHC full mismatch. Although the IVGTT data for the fully mismatched recipient M518 at 6 months after transplantation showed glucose disposal better than when it was naïve, this animal and the fully mismatched recipient M517 in the control group showed less robust nonfasting blood glucose control after transplantation compared to their peers in their respective groups. This poses the question of whether the ratio of SAFasL-presenting microgels to islets may need to be modified in the setting of full MHC mismatch. We know that islet  cells do not express class II antigens under nor mal physiological conditions and hence lack direct recognition via CD4 + T cells (46, 47) . This might be one of the reasons why current clinical islet transplantation does not practice MHC matching and the newly completed two phase 3 Clinical Islet Transplantation Con sortium clinical trials (45, 48) did not provide insights in this regard either. Many factors, such as animal eating habits, pretransplant insulin requirement, the quality and quantity of islet transplanted, baseline donor specific antiHLA antibodies, and others, all con tribute to the posttransplantation metabolic results in our NHP model, but the MHC matching versus metabolic results deserves future study. Furthermore, even with MHC fully matched, grafts will be rejected because of minor antigens in the NHP allogeneic transplant model. However, the impact of the SAFasL microgels is still clearly evident because two of the control animals were MHC haploidentical but still rejected the grafts at ~1 month after transplantation.

Immunological reaction to transplanted allogeneic islets involves both allo and autoreactive pathways. Both auto and alloreactive T cells express Fas on their surface after antigen recognition and activation and become sensitive to apoptosis induced by the Fas/ FasL interaction. Therefore, FasL has the potential for use as an im munomodulator to eliminate these T effectors in the setting of islet transplantation. Our strategy is to deliver FasL locally within the graft microenvironment in a controlled and sustained fashion using advanced synthetic materials. This is a unique advantage over FasL gene therapy, because uncontrolled, continuous expression of FasL, which has pleiotropic activity and various modes of expression that may be differentially regulated by target tissues, may have unintended consequences. Ectopic expression of FasL using gene therapy for immunomodulation has resulted in mixed outcomes, with some studies showing a detrimental impact of FasL expression on graft survival (49) . The localized presentation of SAFasL using microgels also overcomes complications associated with ectopic expression of FasL in target tissues using gene therapy and potential toxicities as re ported for agonistic antibodies to Fas (50) . Last, SAFasL-engineered microgels provide the flexibility of an offtheshelf product for wider clinical applications, as these immunomodulatory materials can be prepared at the time of transplantation and simply admixed with islets for delivery without the need of encapsulating or chemically modifying islets to present proteins.

We note limitations of the present study. Because of logistical, ethical, and cost considerations, NHP allogeneic islet transplanta tion studies comprise a small number of subjects, limiting statisti cally comparisons, and the results may not be representative of a larger cohort of subjects. Furthermore, although the STZinduced NHP diabetes model provides a rigorous test of allogeneic islet transplantation, it does not involve autoimmunity, an important consideration when transplanting in the setting of human T1D. Last, the omentum of a small primate is a thin gossamerlike vascularized membrane that is not fat laden and thick. The human omentum is often dissimilar to that of the primate. Although initial studies sup port omentum as an alternative to intraportal transplantation in humans (23) , additional studies are necessary to establish the validity of this site for clinical islet transplantation. In this study, we decided against transplanting SAFasL-presenting microgels and islets to the liver as currently done clinically over safety concerns that the additional volume of the microgels could increase the risk of portal vein thrombosis. Further studies in NHP portal transplantation modes or modification of the microgel delivery vehicle to increase compat ibility with the portal vein route are necessary. In addition to the omental site, the recent report of using intrapleural space as a site for transplantation of allogeneic pancreatic islets (26) is of interest and could potentially be combined with this strategy.

Study protocols were approved by the Institutional Animal Care and Use Committee at the Massachusetts General Hospital Research Institute. Naïve, captivebred, male or female cynomolgus monkeys (Macaca fascicularis) were purchased from Charles River Laboratory (Houston, TX). All animals were certified under the standards of U.S. Interstate and International Certificate of the Health Examination for Small Animals. Bacteriologic and serological tests were performed on each animal to ensure that they were not infected with parasites, Salmonella/shigella or Tuberculosis bacteria, Simian Tcell leukemia viruses, Simian immunodeficiency virus, herpes B, and SchmidtRuppin virus before being transported to Massachusetts General Hospital Center for Comparative Medicine and Laboratory Animal Services (CCM) for housing. NHPs were fed three times daily (7:00 a.m., 11:00 a.m., and 2:00 p.m.) with certified primate food (LabDiet, catalog no. 5038) and supplemented with fresh fruit daily (9:00 a.m. and 3:30 p.m.).

After an 8week quarantine period at CCM, blood was drawn for ABO typing, MHC genotyping analysis (AIDS Vaccine Research Labs, University of Wisconsin, Madison, WI), and T cell subset analysis before transplantation. Recipients also underwent a 2 to 4month training to cooperate with procedures such as drug ad ministration, hand feeding, and voluntary presentation of their tails to facilitate blood draw for blood glucose measurement. Donors and recipients were paired on the basis of ABO blood group com patibility and MHC mismatching (tables S1 and S2). In each case, islets from one donor were transplanted into one recipient.

NHPs were fasted overnight before administration of STZ at a dose of 75 mg/kg (Zanosar, Teva Parenteral Medicines, Irvine, CA). Sterile STZ powder was diluted in 5.0 ml of 0.9% NaCl and administered through the saphenous vein over 2 min followed by infusion of 30 ml of NaCl. Starting the next day, blood glucose levels were monitored twice daily (8:00 to 9:30 a.m. and 3:30 to 5:00 p.m.) via tail pricking (Accucheck Aviva, Roche Diagnostics, Indianapolis, IN). STZ induced diabetes was defined as three consecutive fasting glucose level readings of >300 mg/dl and Cpeptide levels of <0.5 ng/ml [Mercodia Cpeptide enzymelinked immunosorbent assay (ELISA), Mercodia AB, Uppsala, Sweden]. PostSTZ period is defined from the time of STZ injection until the day of islet transplantation. Posttransplant graft rejection was defined as three consecutive fasting blood glucose read ings of >180 mg/dl or nonfasting blood glucose of >250 mg/dl. Exoge nous insulin (Humulin R, Lilly, Indianapolis, IN) and Lantus (Lilly, Indianapolis, IN) were administered on a sliding scale regimen to achieve a postprandial blood glucose level of <250 mg/dl before trans plant or after graft rejection was defined. Animals having induced dia betes for at least 12 days were used as recipients of islet transplantation.

For all recipient animals, the day of allogeneic islet transplant is defined as day 0. Animals received rapamycin (LC Laboratories, Woburn, MA) at a dose of 0.2 mg/kg intramuscularly daily for a total of 3 months starting on day −3, with target blood trough level of 40 ng/ml for the first 2 weeks and then 20 ng/ml until the 3month time point after transplant, when rapamycin was discontinued without weaning. Subjects received islets and SAFasL-presenting PEG microgels or control microgels at a 1 IEQ:2 PEG microgel ratio. After transplanta tion, daily lowdose exogenous insulin (two to four units) was ad ministrated to all recipients for the first 28 days to promote islet engraftment by allowing islet "rest." Graft recipients were also sub jected to prophylactic ganciclovir treatment for cytomegalovirus.

Donor pancreatectomy was performed on the same day as islet transplantation. In brief, a median sternotomy with a midline abdominal incision was performed. Once a 12gauge cannula connected to infusion set of hypothermic University of Wisconsin (UW) organ preservation solution was placed into the aorta at the renal artery level, 2000 U of heparin (SAGENT Pharmaceuticals, Schaumburg, IL) was given intravenously. Subsequently, the ab dominal aorta was cross clamped at the subdiaphragmatic level. Lesser sac was packed with iced saline, while 1000 ml of UW solu tion was delivered from the aorta cannula for perfusion. The in ferior vena cava was transected to provide proper venous drainage during perfusion. The entire pancreas was mobilized and excised subsequently.

The protocol of islet isolation was based on a modified human islet isolation protocol as we previously reported (7, 51) . Briefly, the pan creas was enzymatically digested using purified Thermolysin and Collagenase blend (Vitacyte, Indianapolis, IN). Islets were purified from the digestion using continuous OptiPrep gradient (densities of 1.11 to 1.06) and a COBE 2991 blood cell processor (Gambro BCT Inc., Lakewood, CO) to separate islet from exocrine tissue. Samples taken from different fractions after purification were used to assess the purity of each cell fraction. Only fractions with >50% purity by dithizone stain were combined for transplantation. Final islet preparations were enumerated by manual counting, sizing, and converting islet particle number to IEQs based on a 150mm diam eter. Islets were then put into 15 ml of CMRL 1066 transplant media (Cellgro, Manassas, VA), supplemented with 10% human serum albumin (Grifols Therapeutics, Research Triangle Park, NC) and heparin 70 units/kg recipient body weight ready for transplantation.

Under general anesthesia, a small midline abdominal incision was performed. The omentum was mobilized and draped over on a sterile moist towel with as minimal manipulation as possible. Islets were resuspended with PEG microgels with or without SAFasL protein at a 1:2 ratio of IEQ to microgel in a minimal volume of NHP autologous plasma and carefully dripped onto the omentum surface. The islets were immobilized on the omentum by topical recombinant thrombin (Recothrom, ZymoGenetics) layered over the islet slurry, followed by another layer of autologous plasma to create a degradable biologic fibrin matrix (23) . The omentum was then folded onto itself and held in place by the thrombininduced fibrin glue to form a microenvironment (omental pouch) to host the islets and SAFasL microgels.

Animals were sedated with ketamine hydrochloride after overnight fasting (no insulin was administered the night before). Catheters (22gauge) were placed into bilateral saphenous veins for glucose delivery and blood sampling separately. Fifty percent of dextrose (Hospira Inc., Lake Forest, IL) solution (0.5 g/kg) was injected over a 30s period at t = 0. Blood samples were taken before dextrose injection and at 1, 3, 5, 10, 15, 20, 30, 60 , and 90 min after injection to measure glucose. Serum samples were frozen at −80°C for subse quent analysis. Insulin and Cpeptide were measured in duplicate with an ELISA kit (Mercodia AB, Uppsala, Sweden, catalog nos. 10 113201 and 10114101).

The SAFasL protein was produced using a Drosophila Expression System expression system and our established protocols (18, 52) . Briefly, S2 cells stably transfected with the SAFasL construct were induced for protein expression using CuSO 4 . Culture supernatant was col lected 72 hours after induction and subjected to protein purification using a FLAGtagged immunoaffinity purification system. The pu rified protein was analyzed by SDS-polyacrylamide gel electrophoresis for purity, assessed for concentration using bicinchoninic acid, and tested for the presence of endotoxin using limulus amebocyte lysate endpoint assay (Cambrex Biosciences). The apoptotic function of SAFasL protein was assessed using the mouse A20 B cell lymphoma line constitutively expressing Fas receptor as an in vitro potency assay. Protein lots having EC 50 (median effective concentration) apoptotic activity of 5 to 20 ng/ml were then assessed for biotin binding capacity using mouse splenocytes surface modified with biotin and analyzed using flow cytometry.

SA-FasL-presenting microgels PEG microgels functionalized with biotin were prepared as de scribed (19, 53) . Briefly, poly(dimethyl siloxane) microfluidic flow focusing devices with 200m nozzles were cast and assembled. Syringe pumps were used to infuse polymer and crosslinking solu tions at a continuous rate such that the flow focusing geometry of the microfluidic device generates polymer droplets. PEGbiotin solution (5% 20 kDa PEG4MAL reacted with 2.0 mM biotin PEG thiol) was infused into the microfluidic device and focused into 160 to 180mdiameter droplets by coflowing with shielding solu tion consisting of light mineral oil and 2% SPAN80 surfactant. The droplets were then crosslinked by introduction into a flow stream of a dithiothreitol [30 mg/ml in phosphatebuffered saline (PBS)] emulsion in mineral oil at a ratio of 1:15. After rapid crosslinking, microgels were collected in a solution of PBS supplemented with 1% human serum albumin. To remove excess oil and crosslinking solution, microgels were washed five times in PBS with 1% human serum albumin by centrifugation. After the final wash, capsules were stored in PBS with 1% human serum albumin at 4°C for up to 2 weeks. To tether SAFasL onto biotinfunctionalized microgels, SAFasL was incubated with biotin microgels in PBS with gentle rocking for 30 min (1 g of SAFasL/1000 microgels) and washed in PBS with 1% human serum albumin. Previously fabricated PEG mi crogels were functionalized with SAFasL on the day of transplant.

Samples from liver, spleen, intestine, lymphoid, lung, heart, omen tum, and native pancreatic tissue were fixed in 10% formaldehyde before being processed and embedded in paraffin. Serial sections of 5 m thickness were cut. H&E staining was performed for routine his tology. Immunohistochemistry was conducted using anti FoxP3 antibody (eBioscience, San Diego, CA). Biotinylated horseradish peroxidase (HRP) or fluorescently labeled secondary antibodies were used, and for HRPconjugated antibodies, signals were detected by diaminobenzidine (Vector Labs, Burlingame, CA). Slides were counterstained with hematoxylin or 4′,6diamidino2phenylindole (DAPI) and mounted.

PBMCs were isolated from whole heparinized blood using a Percoll density gradient method. Briefly, 10 ml of blood was transferred to a 50ml conical tube prefilled with 35ml sterile saline solution. Next, 10 ml of 60% Percoll gradient (SigmaAldrich, St. Louis, MO) was pipetted to underlay the diluted blood. The layered solution was centrifuged at 700g for 30 min at room temperature, with the brake turned off. The PBMCrich buffy layer was harvested, and contami nating red blood cells were removed by standard water shock treat ment. PBMCs were washed three times with 1× PBS, and viable cells were counted by trypan blue exclusion. PBMCs were either frozen at −80° and then stored in liquid nitrogen or used immediately for assays.

Fresh blood cells (<6 hours) were labeled with fluorescein isothio cyanate (FITC)-, phycoerythrin (PE)-, peridin chlorophyll protein (PerCP)-, or allophycocyanin (APC)-conjugated antibodies including CD3, CD4, CD8, CD20, CD95, CD28, or immunoglobulin M (IgM) (BD Pharmingen, San Jose, CA). FACSVerse flow cytometer (Becton Dickinson, San Jose, CA) and FlowJo software (TreeStar Inc., Ashland, OR) were used for immune cell subset analysis.

T cells from recipient PBMCs were purified using the Pan T Cell Isolation Kit (catalog no. 130091993, Miltenyi Biotec) as respond er cells to perform mixed lymphocyte reactions. Responder cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) (Life Technologies, Carlsbad, CA) at a concentration of 5 M per 10 7 cells at room temperature in the dark for 5 min and then plated at a concentration of 3 × 10 5 cells per well in 196well Ubottom plates for coculture with irradiated (3000 cGy) VPD450-labeled stimulator PBMCs from donor or thirdparty NHPs. PBMCs from the responder animal were used as negative controls, and phyto hemagglutinin (PHA) was used for positive controls. After 5 days in coculture at 37°C, 5% CO 2 , the cells were stained with antibodies desired and CFSE dilution was assessed by flow cytometry.

Donor PBMCs were first incubated with recipient serum for 30 min at 4°C, followed by Alexa Fluor 488-conjugated goat antihuman IgG antibody (Jackson ImmunoResearch, West Grove, PA) for 30 min at 4°C. PBMCs were costained with PerCPconjugated antiCD20 and IgM APC antihuman antibodies (BD Pharmingen, San Jose, CA) for 30 min at 4°C. After washing, cells were fixed with 2% paraformaldehyde (Santa Cruz Biotechnology, Santa Cruz, CA) and analyzed with a BD FACSVerse flow cytometer. A stored mix ture serum from more than four previously rejecting monkeys was used as positive control. A positive reaction of the T and B cells was defined as a shift greater than pretransplant serum control.

ELISpot plates (Millipore, Bedford, MA) were precoated with cap ture antibody (5 g/ml) against IFN (Mabtech, Cincinnati, OH) in 1× PBS and stored overnight at 4°C. Plates were washed five times in PBS and blocked with RPMI 1640 (Cellgro, Manassas, VA) containing 10% bovine serum albumin (SigmaAldrich) for 1 hour at 37°C in a humidified incubator followed by three washes in PBS. Responding PBMCs (3.0 × 10 5 cells) were added to each well in 100 l of complete RPMI 1640 supplemented with 10% pooled naïve monkey serum and lglutamine, penicillin/streptomycin, and Hepes buffer (Invitrogen). The responding cells were cultured with an equal number of irradiated stimulating cells, medium alone, or PHA at 1 g/ml (SigmaAldrich). After 48hour incubation at 37°C, the plates were washed and biotinylated detection antibodies against IFN (Mabtech, Cincinnati, OH) were added. The plates were then incubated at room temperature for 2 hours, washed with PBS, and incubated with SAHRP (Mabtech) in PBS for 1 hour at room tempera ture, followed by an additional five washes. Trimethylboron (TMB; Moss, Pasadena, MD) was used to develop the spots. Development was done until distinct spots appeared. Plates were analyzed with an ELISpot image analyzer (Cellular Technology, Cleveland, OH).

A monkey cytokine magnetic 29Plex panel (catalog no. LPC0005M, Invitrogen) was used to measure the concentration of cytokines in the plasma. Samples were diluted 1:2 in assay diluent and then added to the wells. In brief, 25 l of 1× antibody beads was added into each assay well followed by 50 l of incubation buffer. Diluted standards (100 l) were added into standard wells, and 50 l of assay diluent followed by 50 l of sample was added into sample wells. The plate was covered and incubated for 2 hours at room temperature on an orbital plate shaker. Then, the plate was washed twice with 1× wash solu tion. Biotinylated detector antibody (100 l) was added to all assay wells and incubated for 1 hour at room temperature on a shaker. After washing twice with wash solution, 100 l of SARphycoerythrin solution was added to each assay well and incubated for 30 min at room temperature on a shaker. The plate was washed three times with 200 l of wash solution. Wash solution (150 l) was added to each assay well, and then the plate was inserted into the XY plat form of the MAGPIX instrument (Luminex XMAP Technology) and analyzed. The concentration of samples was determined from the standard curve using a curve fitting software.

The presence and quantity of SAFasL protein in the plasma of SA FasL microgel-treated NHPs was assessed using a rat FasL sandwich ELISA kit from RayBiotech, with a sensitivity of 90 pg/ml. Briefly, serum from before and various time points after transplant obtained from NHPs receiving SAFasL microgels were used per manufactur er's instructions. SAFasL in plasma samples was quantified using a standard curve and reported as nanograms per milliliter.

The titers of anti-SAFasL antibodies in NHPs receiving SA FasL microgels were determined using a standard ELISA. Briefly, Costar 96well titer plates (Corning Life Sciences) were coated with SAFasL protein (1 g/ml) in PBS overnight at 4°C. Plates were washed twice with PBS containing 0.5% Tween 20, and wells were incubated with the blocking buffer (PBS containing 5% dry milk + 0.5% Tween 20) overnight at 4°C. Plates were then washed twice with PBS containing 0.5% Tween 20. Fifty microliters of twofold serial dilutions of serum that had been preincubated with the block ing buffer for 30 min was added to each well in duplicate and incu bated for 90 min at room temperature. Wells were then washed two times with PBS + 0.5% Tween 20 and incubated for 1 hour at room temperature with goat antimonkey IgGHRP antibody (Thermo Fisher Scientific, Waltham, MA) diluted in 1:20,000 in the blocking buffer. Wells were washed twice with PBS + 0.5% Tween 20 and incubated with 50 l of TMB substrate (BD Biosciences) for 30 min, and the reaction was stopped with 2 N sulfuric acid. Absorbance was measured at 450 nm, and anti-SAFasL antibodies were reported as log 10 titers of the greatest serial dilution with a mean OD 450 (optical density at 450 nm) value >2fold the OD 450 value of naïve serum. Samples with an antibody titer of log 10 1.4 or less were con sidered negative. The titers of antibodies against SA protein were determined using the same scheme for SAFasL, except that the 96well titer plates were coated with the SA protein.

Data are reported as mean ± SEM. All analyses were performed us ing Prism (version 8.4, GraphPad Software). Graft survival between groups was compared using the logrank (MantelCox) test and GehanBreslowWilcoxon statistics. Normally distributed data that presented equal variances were analyzed via analysis of variance (ANOVA; unpaired t tests for two groups) or logtransformed if the variances were not equal. Dunn's tests were used for post hoc pair wise comparisons. For longitudinal data, repeatedmeasures ANOVA was used with pairwise comparisons to pretransplant/day 0 values using Dunnett's test. P values less than 0.05 were considered statis tically significant.

Supplementary material for this article is available at https://science.org/doi/10.1126/ sciadv.abm9881

View/request a protocol for this paper from Bio-protocol.

Type 1 diabetes: Recent developments

New directions in incidence and prevalence of diagnosed diabetes in the USA

Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy

Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts

Actively acquired tolerance of foreign cells

Tolerance-inducing strategies in islet transplantation

Pilot study evaluating regulatory T cell-promoting immunosuppression and nonimmunogenic donor antigen delivery in a nonhuman primate islet allotransplantation model

Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes

HLA-mismatched renal transplantation without maintenance immunosuppression

Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation

CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates

Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation

Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice

Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells

Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes

Membrane-bound Fas ligand only is essential for Fas-induced apoptosis

Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection

Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice

Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance

Islet cell transplant: Update on current clinical trials

State of the art of clinical islet transplantation and novel protocols of immunosuppression

Bioengineering the endocrine pancreas: Intraomental islet transplantation within a biologic resorbable scaffold

Bioengineering of an intraabdominal endocrine pancreas

Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin-induced neuropathic cold hypersensitivity

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

Intrapleural transplantation of allogeneic pancreatic islets achieves glycemic control in a diabetic non-human primate

B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates

Update on islet transplantation. Cold Spring Harb

Present and future cell therapies for pancreatic beta cell replenishment

Encapsulated islet transplantation: Strategies and clinical trials

Type 1 diabetes

Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege

In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche

Identification of regulatory T cells in tolerated allografts

Bronchus-associated lymphoid tissue-resident Foxp3 + T lymphocytes prevent antibody-mediated lung rejection

Treg-mediated prolonged survival of skin allografts without immunosuppression

Sustained suppression by Foxp3 + regulatory T cells is vital for infectious transplantation tolerance

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice

Recruitment of Foxp3 + T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor

Cell contact-dependent immunosuppression by CD4 + CD25 + regulatory T cells is mediated by cell surface-bound transforming growth factor beta

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

Fas ligand in human serum

Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape

Phase 3 trial of transplantation of human islets in Type 1 diabetes complicated by severe hypoglycemia

Immunohistological observations of rat fetal pancreas allografts transplanted into unmodified and cyclosporine-treated recipients

Altered distribution of class I and class II MHC antigens during acute pancreas allograft rejection in the rat

Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

Lethal effect of the anti-Fas antibody in mice

Purified human pancreatic islets (PHPI) master production batch record-A standard operating procedure of the NIH Clinical Islet Transplantation Consortium

Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein

Microfluidic-based generation of sizecontrolled, biofunctionalized synthetic polymer microgels for cell encapsulation

Serifis for technical contributions. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NSF. Funding: This work was funded by Juvenile Diabetes Research Foundation grant 2-SRA-2016-271-S-B (A

The SA-FasL protein or biotinylated microgels can be provided by the University of Missouri (SA-FasL) or Georgia Tech Research Corp. (microgels) pending scientific review and a completed material transfer agreement. Requests for the SA-FasL protein should be submitted to: haval